Top 5 Most Read Q&As of 2023
Industry experts touched on patient needs, rare diseases, and gender analysis among other topics in these written Q&As.
Below is a list of the most read written Q&As featured on Applied Clinical Trials in 2023.
1. Identifying Patient Needs
Mural Health Technologies, Inc., a new global provider of clinical trials technology, announced the launch of its new participant-facing technology platform, Mural Link at the CNS Summit in November. Sam Whitaker, co-founder and co-CEO of Mural Health, is no stranger to patient-facing technology. He founded Greenphire over 15 years ago to address participant payment technology. In this Q&A with Applied Clinical Trials, Whitaker discusses his time in the industry and patient needs in the current clinical trials market.
Read the Q&A here.
2. Maximizing Success in Rare Disease Studies
Sanjay Shukla, MD, MS, CEO of aTyr Pharma, discusses the company's clinical operations and ongoing Phase III study for pulmonary sarcoidosis. Shukla explains the challenges in conducting a large trial for a rare disease and the company's approach to overcoming them. The trial design, incorporating patient feedback and decentralized clinical trials, are seen as essential for clinical trial and commercialization success.
Read the Q&A here.
3. Q&A with Antonella Santuccione Chadha, MD, chief medical officer, Altoida, and pro bono CEO of the Women’s Brain Project
Clinical trials, says neuroscientist Antonella Santuccione Chadha,MD, usually have one thing in common: Their results are not stratified on the basis of sex. That lack of sex- and gender-based analysis, says Santuccione Chadha, chief medical officer, Altoida, and pro bono CEO of the Women’s Brain Project, negatively impacts the whole of society. Santuccione Chadha spoke with Applied Clinical Trials.
Read the Q&A here.
4. From 'Brave Spaces' to Battling Bias in Patient Engagement
Applied Clinical Trials chatted with Ashley Moultrie, director of diversity, equity, and inclusion (DEI) and community engagement for Javara, an integrated research company that provides clinical research access to patients at the point the care. Javara achieves this by embedding staff and infrastructure into large healthcare organizations.
Read the Q&A here.
5. Bridging the Immunity Gap: An In-Depth Conversation with GeoVax's CEO, David Dodd
David Dodd, CEO of GeoVax, discusses the company's unique vaccine development strategy, clinical trials, and approach to serving patient populations often overlooked by conventional vaccines. The conversation sheds light on the company's specialized focus on immunocompromised patients, their clinical trial operations, and their expectations for the future.
Read the Q&A here.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.
